SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNY - Sanofi
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Stock News
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treatment.
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
Sanofi faces a setback as tolebrutinib fails its Phase 3 PPMS trial, halting regulatory pursuit for this indication. Meanwhile, an approval decision on the candidate has also been delayed. SNY's...
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two...
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints
Shares of French pharmaceutical group Sanofi fell sharply on Monday after the company flagged another delay to a US regulatory decision for its experimental multiple sclerosis drug tolebrutinib...
Cullen Capital Management LLC Acquires 36,714 Shares of Sanofi $SNY
Cullen Capital Management LLC raised its holdings in shares of Sanofi (NASDAQ: SNY) by 9.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange...
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won't be completed by the end of the year and that a trial for a different...
Sanofi flags delay in FDA's decision on tolebrutinib, shares fall
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first...
Sanofi Multiple Sclerosis Drug Hit by Double Setback
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time...
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated...
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
The National Medical Products Administration (NMPA) in China has approved Sanofi SA's (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi...
Sanofi's Bleeding-Disorder Treatments Get Approval in China
Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.
Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six...
InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and...
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
Callodine Capital Management LP Purchases 109,240 Shares of Sanofi $SNY
Callodine Capital Management LP grew its holdings in Sanofi (NASDAQ: SNY) by 26.9% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned...
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation
Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud investigation.
Price Targets
Sanofi resumed with an Equal Weight at Morgan Stanley
$56.00
(was $49.19)
Sarita Kapila
·
Morgan Stanley
Sanofi price target raised to $64 from $56 at Berenberg
$64.00
(was $58.51)
Luisa Hector
·
Berenberg Bank
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
$60.00
(was $52.53)
Jasper Hellweg
·
Argus Research
Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD'
$55.00
(was $48.00)
Jasper Hellweg
·
Argus Research
Sanofi confirms to Bloomberg Zantac settlement in California
$48.07
(was $48.17)
Iain Simpson
·
Barclays